



# Advanced Prostate Cancer Consensus Conference (APCCC)

St.Gallen/Switzerland: 12 – 14 March 2015

For more information & registration please visit our homepage:  
[www.prostatecancerconsensus.org](http://www.prostatecancerconsensus.org)



The **Advanced Prostate Cancer Consensus Conference (APCCC)** will:

- Provide an update on the current **standard of advanced prostate cancer** management.
- Program will be **highly educational**, consisting of invited lectures, debates and discussions led by the panel of international and interdisciplinary **prostate cancer experts**.
- The conference will culminate on Saturday with an **interdisciplinary expert consensus panel meeting** that will discuss and vote on predefined questions relating to key areas where there is lack of evidence or conflict regarding the optimal treatment of men with advanced prostate cancer. **Participants will be able to attend** the panel meeting as part of the conference.
- The **consensus summary** will be submitted for publication after the meeting in a high impact medical journal.
- Attendees will be able to **interact with panel members**, facilitating and encouraging international collaboration.

## Consensus Expert Panel

|                      |                          |                     |                                    |
|----------------------|--------------------------|---------------------|------------------------------------|
| Akaza H, Japan       | Efstathiou E, Greece/US  | Nelson P, US        | Sella A, Israel                    |
| Attard G, UK         | Fanti S, Italy           | Nilsson S, Sweden   | Shore N, US                        |
| Beltran H, US        | Fizazi K, France         | Oh W, US            | Small E, US                        |
| Chi K, Canada        | Gillessen S, Switzerland | Olmos D, Spain      | Smith M, US                        |
| Chinnaiyan A, US     | Gleave M, Canada         | Padhani A, UK       | Soule H, US (Scientific Committee) |
| Daugaard G, Denmark  | Halabi S, US             | Parker C, UK        | Sternberg C, Italy                 |
| Davis I, Australia   | Heidenreich A, Germany   | Rubin M, US         | Suzuki H, Japan                    |
| De Bono J, UK        | Hussain M, US            | Ryan C, US          | Sweeney C, US                      |
| De Santis M, Austria | James N, UK              | Sartor O, US        | Tannock I, Canada                  |
| Drake C, US          | Lecouvet F, Belgium      | Schalken J, Holland | Tombal B, Belgium                  |
| Eeles R, UK          | Logothetis C, US         | Scher H, US         |                                    |

## Recommended by

## Endorsement



Under the auspices of



| Thursday 12 March 2015 10am-6:30pm  |  |
|---|--|
| <b>Session 1</b>  | <b>Current treatment options: State of the Art</b> <ul style="list-style-type: none"> <li>• Role of new endocrine agents in advanced prostate cancer (APC)</li> <li>• Role of chemotherapy in the management of APC</li> <li>• Role of immunotherapies in APC</li> <li>• Sequencing or combination – how to make best use of the available agents?</li> </ul>  |
| <b>Session 2</b>  | <b>Bone metastases: Best management strategies</b> <ul style="list-style-type: none"> <li>• How to best prevent skeletal related events (SRE's) in the era of novel treatment options?</li> <li>• How to make best use of radium223?</li> <li>• Early detection and treatment of patients with malignant spinal cord compression</li> <li>• Patients with DIC and bone marrow failure</li> </ul>   |
| <b>Session 3</b>  | <b>Debates: The role of “vintage” hormonal manipulations</b> <ul style="list-style-type: none"> <li>• At progression after ADT: Is a “vintage” androgen receptor inhibitor useful?</li> <li>• Single agent steroids: “Dead or Alive”?</li> <li>• Ketoconazole: “Dead or Alive”?</li> <li>• Estrogens/Estramustine: “Dead or Alive”?</li> </ul>   |
| <b>Session 4</b>  | <b>Management of special APC clinical situations</b> <ul style="list-style-type: none"> <li>• When to use radiotherapy in APC</li> <li>• Management of local complications in APC</li> <li>• Small cell and anaplastic prostate cancer</li> <li>• Meningeal carcinomatosis and brain metastases</li> <li>• Management of young (&lt;55) and old (&gt;85) and/or frail patients</li> <li>• Patients with BRCA1/2 and other germline mutations</li> </ul>                    |
| Friday 13 March 2015 8am-6.45pm   |  |
| <b>Session 5</b>  | <b>Management of hormone sensitive metastatic prostate cancer</b> <ul style="list-style-type: none"> <li>• Use of GnRH antagonists and single agent AR-Antagonists</li> <li>• Intermittent versus continuous ADT</li> <li>• When to use combined androgen blockade?</li> <li>• Bone targeting agents in hormone sensitive metastatic prostate cancer</li> <li>• What's the role of docetaxel in the management of hormone sensitive metastatic prostate cancer?</li> </ul> |
| <b>Session 6</b>  | <b>Molecular characterisation of APC – Relevance today!</b> <ul style="list-style-type: none"> <li>• Androgen receptor and other steroid receptors: The key drivers of APC?</li> <li>• Current state of molecular characterisation of prostate cancer</li> <li>• Serum based biomarkers and CTCs</li> <li>• Smarter Clinical Trials: Translating biology into Therapeutics</li> </ul>  |
| <b>Session 7</b>  | <b>M0 CRPC – an overview and debate</b> <ul style="list-style-type: none"> <li>• What imaging and when in M0 CRPC?</li> <li>• What treatments are recommended for M0 CRPC?</li> </ul> <b>Debate:</b> Novel survival prolonging treatments for M0 CRPC  |
| <b>Session 8</b>  | <b>Monitoring of disease activity: a challenging task</b> <ul style="list-style-type: none"> <li>• Current imaging for APC – an unsolved daily clinical problem: The radiologists view</li> <li>• Current imaging for APC – an unsolved daily clinical problem: The nuclear medicine view</li> <li>• Prostate Cancer Working Group criteria – What's the next generation?</li> <li>• When to change treatment for APC patients in daily practice?</li> </ul>               |
| <b>Session 9</b>  | <b>How to transfer study results into clinical practice?</b> <ul style="list-style-type: none"> <li>• Interpreting clinical trials: New concepts, old pitfalls</li> <li>• Factors that drive clinical decision making</li> <li>• Mechanisms of resistance to ADT and how this informs us clinically</li> <li>• Shift from prognostication to prediction in APC: Are we ready?</li> </ul>   |
| <b>Session 10</b>   | <b>Debate:</b> Abiraterone or Enzalutamide as first-line treatment<br><b>Debate:</b> Chemotherapy before use of survival prolonging novel endocrine agents in CRPC patients  |
| Saturday 14 <sup>th</sup> of March 2015 9am-1pm   |  |
| <b>Consensus Panel – Discussion and votes on consensus questions (open to participants)</b> |  |